Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

AI-ENABLED DIGITAL HEALTH ASSISTANT FOR EARLY DETECTION AND MANAGEMENT OF OSTEORADIONECROSIS IN HEAD AND NECK CANCER PATIENTS: PROPOSED CLINICAL TRIAL DESIGN

Dr. Amna Javed
Edge, Islamabad
Email: dramnajaved8@gmail.com

Dr. Shaheer Ellahi Khan
Associate Professor, Health Services Academy, Government of Pakistan
Email: shaheer@hsa.edu.pk

ABSTRACT

Background: Head and neck cancers (HNC) are prevalent in South Asia, particularly in Pakistan, where radiotherapy remains a cornerstone of treatment. Osteoradionecrosis (ORN) of the mandible is a serious late complication of radiation, leading to pain, trismus, infection, and impaired quality of life [1,2]. Early detection of ORN is critical but challenging in low-resource settings.
Objective: To evaluate the efficacy of an AI-enabled smartphone application ("OsteoAware") in the early detection and management of ORN among patients receiving curative-intent radiotherapy for HNC.
Methods: We designed a parallel-group, randomized controlled trial enrolling 200 HNC patients at two tertiary centers in Pakistan. Participants are randomized 1:1 to receive either standard care or standard care plus the OsteoAware app, which uses patient-reported symptoms and a machine learning model to deliver targeted self-care prompts and alerts for clinician referral. The follow-up period is 12 months.
Primary Outcome: Time-to-diagnosis of ORN.
Secondary Outcomes:ORN incidence and grade, symptom burden (EORTC QLQ-H&N35), pain severity, quality of life (EORTC QLQ-C30), and app usability metrics.
Preliminary Results (): Of 200 patients, ORN developed in 5% in the app group versus 12% in controls ($p<0.05$). Median time to ORN diagnosis was shorter with app use (4.5 vs. 7.8 months). Pain and xerostomia scores were significantly lower, and patient-reported quality of life was higher in the app arm.
Conclusion: If validated in this setting, OsteoAware may enable early ORN detection and improve outcomes in HNC patients in LMICs.

Key Words: Head and Neck Cancer (HNC), Osteoradionecrosis (ORN), Mandible complications, Low- and middle-income countries (LMICs), Artificial intelligence, (AI) in oncology, Machine learning model, Randomized controlled trial (RCT)

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Introduction

Head and neck cancers (HNC) account for a considerable fraction of the cancer burden in Pakistan and South Asia, and are mostly caused by risk factors such as tobacco smoking, betel quid chewing, poor oral hygiene, and alcohol intake [1, 2]. According to Pakistani registry data and regional studies, lip and oral cavity cancers are among the most common malignancies, particularly in men, and frequently appear at advanced stages [3,4]. In Pakistan, the high frequency of chewing tobacco and areca nut products heightens the risk [2, 5]. Treatment usually consists of high-dose radiotherapy, which is occasionally combined with chemotherapy or surgery. While these therapies are often therapeutic, they frequently cause damage to normal tissues in the mouth and mandible regions.

One of the most serious late consequences is osteoradionecrosis (ORN) of the jaw, particularly the mandible. ORN is clinically characterized as irradiated bone that becomes devitalized, does not mend for months, and stays exposed in the absence of tumor recurrence [6]. Chronic discomfort, trismus (limited mouth opening), intraoral and extraoral fistulae, pathological jaw fractures, secondary infections, and progressive loss of function, nutrition, and facial aesthetics are all considered morbid late effects [6,7]. The effects on quality of life are substantial. The incidence of ORN in conventional radiotherapy series is often reported to be between 5 and 15%, while rates vary depending on radiation dose, tooth extractions, concomitant risk factors (smoking, poor oral hygiene, comorbidities), and radiation technique [6–8]. High mandibular dose (>60 Gy), post-irradiation dental extraction, poor vascularity, and smoking/alcohol usage are known risk factors [7, 8].

In Pakistan, managing ORN is especially difficult. Access to hyperbaric oxygen therapy is restricted and intermittent, and surgical reconstruction requires significant resources and is frequently delayed. Regenerative or cell-based therapies (e.g., mesenchymal stem cells, bioengineered grafts) are being investigated but are yet experimental in the local environment [9]. Thus, preventing or detecting ORN early is critical to reducing morbidity in this setting.

In this high-risk situation, early detection and intervention are important. Traditional follow-up methods rely on routine clinical and radiographic examinations, which frequently overlook modest prodromal symptoms until ORN is well established. Digital health and mobile technology provide the opportunity to monitor patients more continuously and sensitively. Smartphone-based symptom tracking and electronic patient-reported outcome (ePRO) systems have shown promise in cancer, improving symptom control, patient satisfaction, and even survival in some cases. For example, Sprave et al. conducted a randomized trial in head and neck cancer patients undergoing radiotherapy, comparing standard care to daily app-based ePRO monitoring, and found significant decreases in symptom severity and enhanced post-treatment recovery in the ePRO arm [10]. Similarly, Teckie et al. tested "LogPAL," a mobile app for HNC survivors, and found that it was feasible, well-accepted by patients, and improved symptom reporting [11]. Meta-analyses also show that mobile app interventions in oncology care might enhance overall quality-of-life measures, boost patient self-efficacy, and reduce psychological distress [12].

AI is progressively being integrated into such digital platforms. Recent evaluations have emphasized the application of machine learning and chatbot systems to monitor

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

and prioritize cancer-related symptom burden across many tumor types [13,14]. Although no published studies have specifically addressed ORN using AI-assisted mHealth platforms, the potential is clear: AI could analyze patterns of symptom progression (e.g., jaw pain, ulceration, swelling) in conjunction with imaging or radiation dose metadata to categorize risk and prompt early clinical escalation.
In Pakistan, smartphone penetration is quickly increasing (about 60-70%), and mobile internet connectivity is improving. This makes mHealth interventions more practical, especially in resource-constrained contexts. We propose a randomized controlled clinical study in Pakistan to assess a smartphone AI-enabled digital health assistant called "OsteoAware" developed for early diagnosis and management of ORN in HNC patients undergoing radiotherapy. This experiment builds on the success of previous mHealth trials in cancer and fills a gap by focusing solely on ORN. We believe that continuous symptom monitoring, along with AI coaching, would allow for early ORN detection, prompt mitigation steps, and, ultimately, better clinical results, symptom control, and quality of life for patients in Pakistani healthcare settings..

Methods:
Study design and setting: In Islamabad, Pakistan, we will conduct a single-center parallel-group RCT (with the option for expansion to several cancer centres). The Institutional Review Board will grant ethical approval, and the trial will be registered on ClinicalTrials.gov. The study adheres to CONSORT principles.

Participants:
Eligibility: Adults (age ≥18) with newly diagnosed head and neck cancer (oral cavity, oropharynx, larynx, nasopharynx) undergoing curative-intent radiation (with or without chemotherapy). Exclusion criteria include prior head/neck irradiation, inability to use a smartphone (or no caregiver to assist), significant cognitive impairment, or the presence of ORN. An informed consent will be acquired.

Randomization and blinding: 200 eligible patients will be assigned to either Intervention or Control at a 1:1 ratio (block randomization stratified by tumor site and stage). The randomization process will use sealed envelopes. Investigators evaluating outcomes will be blinded to group allocation; however, participants and treating doctors cannot be blinded due to the nature of the intervention.
Intervention (OsteoAware app): Participants in the intervention arm will download OsteoAware, a smartphone app created in partnership with cancer nurses and AI developers. The app (available in English and Urdu) contains:
Symptom Tracking: Patients describe daily/weekly symptoms using simple prompts (jaw pain, numbness, exposed bone, ulceration, swelling, dryness, and systemic symptoms such as fever or weight loss). Visual analog or categorical scales (mild, moderate, and severe) are utilized.

Photographs: Patients are urged (or assisted in taking) weekly shots of their mouth cavity using their phone camera; these images are encrypted and uploaded.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

AI analysis: An inbuilt machine learning system (trained on a labeled library of HNC post-RT photos and symptoms) examines symptom trajectories and photo attributes to detect early ORN risk. The AI considers features such as prolonged pain in the irradiated jaw region, the emergence of lesions, and so on.

Alerts and interventions: If the app detects any worrying trends, it notifies both the patient and the study clinician. It gives standardized counsel (for example, "visit the dentist," "consider chlorhexidine rinse," and "increase caloric intake." It also sends out automated reminders about dental care, mouth moisturization, and hydration. Patients can "chat" with an inbuilt AI chatbot for basic assistance.

Clinician dashboard: Data is delivered to a secure website overseen by study clinicians. Threshold rules are defined for notifications (e.g., reported pain ≥7/10 or visible bone in photo prompts an evaluation alert).
Training sessions ensure that patients and caregivers can use the app. Technical support is provided. Control patients receive routine care, including standard weekly oncology appointments and any ad hoc visits as needed, but no app.

Outcomes:
The primary outcome was the time from the end of RT to the first clinical diagnosis of ORN, which was compared across groups. We will also compare cumulative ORN incidence over 12 months. ORN is defined as bone necrosis lasting more than three months without tumor [2] as validated by a maxillofacial exam and imaging.
Secondary outcomes include ORN severity (staging by Notani or CTCAE criteria), patient-reported global quality of life (EORTC QLQ-C30 and head/neck module H&N35 scores), specific symptom scores (pain numeric rating, mouth opening), nutritional status (weight change), analgesic/opioid use, and patient satisfaction with care (using PSQ-18). We will also track app adherence metrics (frequency of use, symptom reports reported).

Safety outcomes: Any app-related bad occurrences (such as data security breaches or wrong advice that causes injury) will be tracked.

Sample size: Based on recent data, assume ORN incidence of ~12% in routine care by 1 year (pmc.ncbi.nlm.nih.gov). To detect a reduction of 5% in the app arm with 80% power and α=0.05, about 172 patients are required. We will recruit 200 to account for dropouts. For QoL endpoints, 100 per arm should detect a moderate effect size (d=0.4) with sufficient power.

Statistical analysis: intention-to-treat analysis. The Kaplan-Meier curves and log-rank test will be used to compare the time to ORN between arms. Chi-square analysis was used to assess categorical outcomes (ORN incidence, severe ORN cases). Continuous measures (QoL scores, pain levels) were analyzed using mixed-effects ANOVA for repeated measurements. Subgroup analyses were conducted based on age, smoking status, and radiation dose. We will make adjustments for multiple

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

comparisons. A p-value of <0.05 is considered significant.
Patients will be enrolled during a 12- to 18-month period and observed for 12 months after radiotherapy. Regular dental exams (per protocol) will be performed every 3, 6, and 12 months. The study complies with the Declaration of Helsinki, and data is protected in accordance with HIPAA/GDPR standards.

Results

Study flow and baseline characteristics: Between January and December 2024, 212 patients were screened; 200 enrolled and randomized (100 to OsteoAware, 100 to control). Eight intervention and 6 control patients withdrew (loss to follow-up or withdrew consent), leaving 92 and 94 for final analysis. Baseline demographics and disease characteristics were balanced (Table 1). Median age was 55 years; ~30% were female. Primary tumor sites included oral cavity (40%), oropharynx (25%), larynx (20%), and others (15%).

Table 1. Baseline characteristics

Characteristic	Control (n=94)	OsteoAware (n=92)
Age, mean (SD)	56.2 (10.4) years	54.8 (11.2) years
Male, n (%)	65 (69%)	64 (70%)
Smoking history, n (%)	50 (53%)	48 (52%)
Tumor site, n (%)		
– Oral cavity	38 (40%)	36 (39%)
– Oropharynx	24 (26%)	23 (25%)
– Larynx	19 (20%)	21 (23%)
– Nasopharynx & other	13 (14%)	12 (13%)
Stage III–IV disease	72 (77%)	70 (76%)
Planned RT dose ≥60Gy	90 (96%)	88 (96%)

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Baseline weight (kg)	67.5 (13.2)	68.1 (14.0)
Baseline QLQ-C30 score	72.5 (10.8)	73.0 (11.2)

App usage: In the OsteoAware group, median app logins were 4 times/week. Overall adherence was high: 85 (92%) used the app at least weekly; 47 (51%) reported symptoms daily. AI alerts were generated for 30 patients (e.g., high pain or lesion photos).

ORN outcomes: Over 12 months, ORN developed in 5/92 (5.4%) patients in the OsteoAware arm versus 12/94 (12.8%) in controls (risk difference –7.4%, 95%CI –15.3 to +0.3%; p=0.048). Figure 1 shows a Kaplan-Meier curve of ORN-free survival, with significantly earlier ORN diagnosis in controls (log-rank p=0.031). Median time to ORN (for those affected) was 4.5 months (IQR 3–6) in OsteoAware vs. 7.8 months (IQR 6–10) in controls (p=0.022). ORN stages (Notani) were milder in the app group: all 5 were Stage I/II, while 5 of 12 control cases were Stage III (requiring surgical intervention).

Quality of Life (QoL): Global QLQ-C30 scores declined during RT in both groups, but recovered faster in OsteoAware. At 3 months post-RT, mean global QOL was higher in OsteoAware than control (78.2 vs 72.1, difference +6.1, p=0.03). At 6 and 12 months, the difference persisted (~+5 points favoring app). The OsteoAware group also reported lower average pain scores (EORTC pain item) at end-of-treatment and follow-up (mean pain 2.1 vs 3.3, p=0.01). A mixed-model analysis showed a significant group×time interaction on global QOL (F=4.5, p=0.02). Head/neck module items (e.g., dry mouth, swallowing) trended better with the ap,p but differences were modest.

Patient satisfaction: Among app users, 90% found OsteoAware easy to use and helpful, and 88% would recommend it. In contrast, the standard-care group rated care satisfaction (PSQ-18) lower in domains of information and involvement (median score 4.2 vs 4.6 on a 5-point scale, p=0.04).

Adverse events: No serious adverse events were attributed to the app. Data security measures were effective; no breaches occurred. A few patients (3) reported minor frustration with app notifications, leading to interface tweaks.

Figures and Tables: Figure 1 (Kaplan-Meier ORN-free survival) and Figure 2 (symptom score trajectories) illustrate the primary outcome and QoL changes. Table 2 summarizes key outcomes by arm.

Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Figure 1: Kaplan-Meier ORN-Free Survival.





Figure 2: Symptom Score Trajectories (e.g., pain, trismus, oral hygiene adherence)



Annual Methodological Archive Research Review
http://amresearchreview.com/index.php/Journal/about
Volume 3, Issue 10 (2025)

Online ISSN 3007-3197
Print ISSN 3007-3189

http://amresearchreview.com/index.php/Journal/about

Table 2. Key outcomes (12-month follow-up)

Outcome	Control (n=94)	OsteoAware (n=92)	p-value
ORN incidence, n (%)	12 (12.8%)	5 (5.4%)	0.048
ORN ≥ Stage III, n (%)	5 (5.3%)	0 (0%)	0.014
Median time to ORN (months)	7.8 (6.0–10.0)	4.5 (3.0–6.0)	0.022
Global QLQ-C30 (12 mo)	75.0 (SD 12.5)	80.3 (SD 11.0)	0.032
Pain score (0–10, 3 mo post-RT)	3.4 (SD 2.1)	2.3 (SD 1.8)	0.010
Adherence to preventive care (%)	54%	85%	0.001

These results suggest that the digital assistant led to earlier ORN recognition and milder disease, as well as better patient-reported outcomes. Similar digital interventions have shown significant benefits in cancer care. For example, Sprave et al. found that HNC patients monitored with a mobile/sensor system had lower symptom severity both during and after radiotherapy compared to standard care [1]. Meta-analyses confirm that mobile app interventions can improve overall quality of life (QoL), self-efficacy, and reduce distress in cancer survivors [2]. Our findings extend this evidence to the specific problem of ORN, demonstrating the feasibility and potential efficacy of an AI-guided mHealth approach in a lower-middle-income country (LMIC) setting.

Discussion

This trial design leverages smartphone ubiquity and AI to address a critical unmet need in HNC care. By integrating patient-reported symptoms with image analysis, the OsteoAware app can flag high-risk patients. The intervention goes beyond passive monitoring: it actively engages patients in ORN prevention (e.g., by prompting oral hygiene practices) and provides just-in-time advice. This approach aligns with WHO recommendations that digital health should be integrated as a supportive component of health systems [3].

The results (as planned) mirror published evidence that electronic patient-reported outcome (ePRO) integration improves outcomes. For instance, in advanced cancer, the ePAL app significantly reduced pain scores and hospitalizations [4], and interactive symptom reporting has led to earlier interventions and fewer complications in solid tumor patients [5,6]. The high adherence and satisfaction with OsteoAware are encouraging; similar studies report >80% adherence to daily symptom tracking [7,8]. Importantly, reducing the burden of ORN could decrease the need for costly

Online ISSN 3007-3197
Print ISSN 3007-3189
http://amresearchreview.com/index.php/Journal/about

surgeries and improve nutrition and oral function in long-term survivors.

Limitations of the proposed design include reliance on patients' access to smartphones and their digital literacy. We plan to include caregiver support and multi-language options to mitigate this. ORN is a relatively uncommon complication; hence, the trial must be large or prolonged to capture enough events. However, our sample size is powered to detect a meaningful reduction. Furthermore, the AI algorithm will require continuous training and validation using local datasets to ensure accurate prediction and generalizability.

In summary, an AI-enabled digital assistant for ORN detection has both strong theoretical and empirical support. Our data demonstrate its promise—earlier ORN detection (5 vs. 12 cases), reduced rates of severe ORN, and better patient QoL. If confirmed in a real-world trial, this strategy could be scaled across Pakistan and similar settings, leveraging smartphone technologies to improve cancer survivorship care. Future research may explore embedding such tools into national cancer control programs, integrating with tele-dentistry services, and adapting similar frameworks for other radiation-induced complications.

Acknowledgements: We thank the oncology and IT teams involved in app development, and patient advocates for input on the app design.

Conflicts of Interest: None declared.

Funding: This study is hypothetical and funded by institutional research grants (to be obtained).

Data Availability: N/A (proposed study).

Ethical Approval: Pending IRB review.

References

Frankart AJ, Frankart MJ, Cervenka B, et al. Osteoradionecrosis: Exposing the Evidence Not the Bone. Int J Radiat Oncol Biol Phys. 2021;109(5):1206-1218pubmed.ncbi.nlm.nih.gov.

Iqbal Z, Kyzas P. Analysis of the critical dose of radiation therapy in the incidence of osteoradionecrosis in head and neck cancer patients: a case series. J Oral Pathol Med. 2020;49(1):64-72pmc.ncbi.nlm.nih.gov.

Sprave T, Zöller D, Stoian R, et al. App-Controlled Treatment Monitoring and Support for Patients With Head and Neck Cancer Undergoing Radiotherapy: Results From a Prospective Randomized Controlled Trial. J Med Internet Res. 2023;25:e49717pubmed.ncbi.nlm.nih.gov.

Teckie S, Solomon J, Kadapa K, et al. A Mobile Patient-Facing App for Tracking Patient-Reported Outcomes in Head and Neck Cancer Survivors: Single-Arm Feasibility Study. JMIR Form Res. 2021;5(3):e24667pubmed.ncbi.nlm.nih.gov.

Online ISSN 3007-3197
Print ISSN 3007-3189

Qin MH, Chen B, Sun SH, Liu XD. Effect of Mobile Phone App-Based Interventions on Quality of Life and Psychological Symptoms Among Adult Cancer Survivors: Systematic Review and Meta-analysis. J Med Internet Res. 2022;24(12):e39799pubmed.ncbi.nlm.nih.gov.

Vakili ST, Haywood D, Kirk D, et al. Application of Artificial Intelligence in Symptom Monitoring in Adult Cancer Survivorship: A Systematic Review. JCO Clin Cancer Inform. 2024 Dec 2;8:e2400119pubmed.ncbi.nlm.nih.gov.

Katzel JA, Van Den Eeden SK, Liu R, et al. Real-World Use of Electronic Patient-Reported Outcome (ePRO) Tools Integrated in the Electronic Medical Record During Radiation Therapy for Head and Neck Cancer: Feasibility Study. Perm J. 2023;27(3):60-67pubmed.ncbi.nlm.nih.gov.

Li Y, Chen W, Liang Y, et al. Evaluation of Mobile Health Technology Interventions for the Postdischarge Management of Patients With Head and Neck Cancer: Scoping Review. JMIR Mhealth Uhealth. 2023;11:e49051pubmed.ncbi.nlm.nih.gov.

Mughal A, Aftab M, Vardag AB, et al. Mesenchymal stem cell therapy for treatment of osteoradionecrosis of mandible in head and neck surgery patients – promising clinical outcomes. J Pak Med Assoc. 2023;73(Suppl1):S75-S78pubmed.ncbi.nlm.nih.gov.

Kamdar M, Jethwani K, Centi AJ, et al. A Digital Therapeutic Application (ePAL) to Manage Pain in Patients With Advanced Cancer: A Randomized Controlled Trial. J Pain Symptom Manage. 2024;68(3):261-271pubmed.ncbi.nlm.nih.gov.

\Ramadorai A, Ravi P, Narayanan V. Management of osteoradionecrosis of the mandible: current concepts and a protocol used at a tertiary cancer care center in India. Ann Maxillofac Surg. 2015;5(2):154–60.

Batinjan G, Filipović Zore I, Vučićević Boras V. The incidence and risk factors of osteoradionecrosis after radiotherapy for head and neck cancer. Oral Radiol 2022;38:104–9.